Connective tissue disorders and cardiovascular complications: The indomitable role of transforming growth factor-beta signaling

Advances in Experimental Medicine and Biology

Volumn 802, Issue , 2014, Pages 107-127

  Wheeler, Jason B ^a   Ikonomidis, John S ^a   Jones, Jeffrey A ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Curacao diagnostic criteria; Familial thoracic aortic aneurysm and dissection syndrome (FTAAD); Fibrodysplasia ossificans progressiva (FOP); Loeys Dietz syndrome (LDS); Marfan syndrome (MFS); Primary pulmonary hypertension; Shprintzen Goldberg syndrome, hereditary hemorrhagic telangiectasia (HHT); Smad; TGF receptor

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAVEOLIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOGLIN; FIBRILLIN 1; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; SMAD ANCHOR FOR RECEPTOR ACTIVATION; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; COLLAGENASE 3; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANEURYSM OSTEOARTHRITIS SYNDROME; AORTA VALVE REGURGITATION; ARTERIAL TORTUOSITY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CONNECTIVE TISSUE DISEASE; CYTOKINE RELEASE; EHLERS DANLOS SYNDROME; ENDOVASCULAR ANEURYSM REPAIR; FAMILIAL THORACIC AORTIC ANEURYSM AND DISSECTION SYNDROME; GENETIC SCREENING; HEREDITARY CONNECTIVE TISSUE DISEASE; HUMAN; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; SHPRINTZEN GOLDBERG SYNDROME; SIGNAL TRANSDUCTION; THORACIC AORTA ANEURYSM; THORACIC AORTA SURGERY; AORTA DISSECTING ANEURYSM; ARTIFICIAL EMBOLISM; ENZYME ACTIVATION; GALACTOSIALIDOSIS; GENE MUTATION; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; VELOCARDIOFACIAL SYNDROME;

EID: 84934438713     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-7-7893-1_8     Document Type: Article

References (158)

1. Judge DP, Dietz HC (2005) Marfan's syndrome. Lancet 366(9501):1965-1976
2. Dietz HC (1993) Marfan syndrome. In: Pagon RA (ed) Gene reviews. University of Washington, Seattle
3. Unsold C et al (2001) Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 114(Pt 1):187-197
4. Taipale J et al (1996) Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfi brils. J Histochem Cytochem 44(8):875-889
5. Dallas SL et al (1995) Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131(2):539-549
6. Isogai Z et al (2003) Latent transforming growth factor beta-binding protein 1 interacts with fi brillin and is a microfi bril-Associated protein. J Biol Chem 278(4):2750-2757
7. Neptune ER et al (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33(3):407-411
8. Loeys BL et al (2005) A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37(3):275-281
9. Wrana JL et al (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71(6):1003-1014
10. Ramirez F, Rifkin DB (2003) Cell signaling events: A view from the matrix. Matrix Biol 22(2):101-107
11. Hynes RO (2009) The extracellular matrix: Not just pretty fi brils. Science 326(5957):1216-1219
12. Brekken RA, Sage EH (2001) SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol 19(8):816-827
13. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116(Pt 2):217-224
14. Wrana JL et al (1994) Mechanism of activation of the TGF-beta receptor. Nature 370(6488):341-347
15. Moustakas A, Souchelnytskyi S, Heldin CH (2001) Smad regulation in TGF-beta signal transduction. J Cell Sci 114(Pt 24):4359-4369
16. Feng XH, Derynck R (2005) Specifi city and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 21:659-693
17. Park SH (2005) Fine tuning and cross-Talking of TGF-beta signal by inhibitory Smads. J Biochem Mol Biol 38(1):9-16
18. Imamura T et al (1997) Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389(6651):622-626
19. Hata A et al (1998) Smad6 inhibits BMP/Smad1 signaling by specifi cally competing with the Smad4 tumor suppressor. Genes Dev 12(2):186-197
20. Wicks SJ et al (2006) Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. Biochem Soc Trans 34(Pt 5):761-763
21. Ebisawa T et al (2001) Smurf1 interacts with transforming growth factor-beta type-I receptor through Smad7 and induces receptor degradation. J Biol Chem 276(16):12477-12480
22. Kavsak P et al (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365-1375
23. Droguett R et al (2006) Extracellular proteoglycans modify TGF-beta bio-Availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 25(6):332-341
24. Stander M et al (1999) Transforming growth factorbeta and p-21: Multiple molecular targets of decorinmediated suppression of neoplastic growth. Cell Tissue Res 296(2):221-227
25. Lopez-Casillas F et al (1994) Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 124(4):557-568
26. Yu L, Hebert MC, Zhang YE (2002) TGF-beta receptor-Activated p38 MAP kinase mediates Smad- independent TGF-beta responses. EMBO J 21(14):3749-3759
27. Dumont N, Bakin AV, Arteaga CL (2003) Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 278(5):3275-3285
28. Griswold-Prenner I et al (1998) Physical and functional interactions between type-I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol 18(11):6595-6604
29. Itoh S et al (2003) Elucidation of Smad requirement in transforming growth factor-beta type-I receptorinduced responses. J Biol Chem 278(6):3751-3761
30. Wilkes MC et al (2003) Cell-Type-specifi c activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 23(23):8878-8889
31. Choy L, Derynck R (1998) The type-II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response. J Biol Chem 273(47):31455-31462
32. Ozdamar B et al (2005) Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307(5715):1603-1609
33. Hocevar BA, Brown TL, Howe PH (1999) TGF-beta induces fi bronectin synthesis through a c-Jun N-Terminal kinase-dependent, Smad4-independent pathway. EMBO J 18(5):1345-1356
34. Imamichi Y et al (2005) TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem 386(3):225-236
35. Remy I, Montmarquette A, Michnick SW (2004) PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6(4):358-365
36. Runyan CE, Schnaper HW, Poncelet AC (2004) The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factorbeta1. J Biol Chem 279(4):2632-2639
37. Yakymovych I et al (2001) Regulation of Smad signaling by protein kinase C. FASEB J 15(3): 553-555
38. Carta L et al (2009) p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fi brillin-1 (Fbn1)-null mice. J Biol Chem 284(9):5630-5636
39. Yamashita M et al (2008) TRAF6 mediates Smadindependent activation of JNK and p38 by TGFbeta. Mol Cell 31(6):918-924
40. Sorrentino A et al (2008) The type-I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 10(10):1199-1207
41. Lee MK et al (2007) TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26(17):3957-3967
42. Wilkes MC et al (2005) Transforming growth factorbeta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fi broblast responses via p21-Activated kinase-2. Cancer Res 65(22):10431-10440
43. Bertolino P et al (2005) Transforming growth factorbeta signal transduction in angiogenesis and vascular disorders. Chest 128(6 Suppl):585S-590S
44. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1(3):169-178
45. Ignotz RA, Massague J (1986) Transforming growth factor-beta stimulates the expression of fi bronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261(9):4337-4345
46. Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211(1):19-26
47. Kwak HJ et al (2006) Transforming growth factorbeta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signalregulated kinase and Sp1 in human fi brosarcoma cells. Mol Cancer Res MCR 4(3):209-220
48. Kim ES, Kim MS, Moon A (2004) TGF-betainduced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 25(5):1375-1382
49. Laiho M, Saksela O, Keski-Oja J (1986) Transforming growth factor beta alters plasminogen activator activity in human skin fi broblasts. Exp Cell Res 164(2): 399-407
50. Jones JA, Spinale FG, Ikonomidis JS (2009) Transforming growth factor-beta signaling in thoracic aortic aneurysm development: A paradox in pathogenesis. J Vasc Res 46(2):119-137
51. Selvamurugan N et al (2004) Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-Talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem 279(18):19327-19334
52. Pignolo RJ, Shore EM, Kaplan FS (2011) Fibrodysplasia ossifi cans progressiva: Clinical and genetic aspects. Orphanet J Rare Dis 6:80
53. Werner S, Alzheimer C (2006) Roles of activin in tissue repair, fi brosis, and infl ammatory disease. Cytokine Growth Factor Rev 17(3):157-171
54. Milewicz DM, Regalado E (1993) Thoracic aortic aneurysms and aortic dissections. In: Pagon RA (ed) Gene reviews. University of Washington, Seattle
55. Attias D et al (2009) Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 120(25):2541-2549
56. von Kodolitsch Y et al (2004) Chest radiography for the diagnosis of acute aortic syndrome. Am J Med 116(2):73-77
57. Bruno L et al (1984) Cardiac, skeletal, and ocular abnormalities in patients with Marfan's syndrome and in their relatives. Comparison with the cardiac abnormalities in patients with kyphoscoliosis. Br Heart J 51(2):220-230
58. Pannu H, Tran-Fadulu V, Milewicz DM (2005) Genetic basis of thoracic aortic aneurysms and aortic dissections. Am J Med Genet C Semin Med Genet 139C(1):10-16
59. Loeys BL et al (2006) Aneurysm syndromes caused by mutations in the TGF-beta receptor. New Engl J Med 355(8):788-798
60. Biddinger A et al (1997) Familial thoracic aortic dilatations and dissections: A case control study. J Vasc Surg 25(3):506-511
61. Hagan PG et al (2000) The International Registry of Acute Aortic Dissection (IRAD): New insights into an old disease. JAMA 283(7):897-903
62. Guo DC et al (2009) Mutations in smooth muscle alpha-Actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84(5):617-627
63. Milewicz DM et al (2010) De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A 152A(10):2437-2443
64. Loscalzo ML et al (2007) Familial thoracic aortic dilation and bicommissural aortic valve: A prospective analysis of natural history and inheritance. Am J Med Genet A 143A(17):1960-1967
65. Zhu L et al (2006) Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 38(3):343-349
66. Isselbacher EM (2005) Thoracic and abdominal aortic aneurysms. Circulation 111(6):816-828
67. Denton CP et al (2003) Fibroblast-specifi c expression of a kinase-defi cient type-II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fi brosis in transgenic mice. J Biol Chem 278(27):25109-25119
68. Wong SH et al (2000) Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem/FEBS 267(17):5550-5560
69. Di Guglielmo GM et al (2003) Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5(5):410-421
70. Nakao A et al (1997) Identifi cation of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389(6651):631-635
71. van De Laar IM et al (2011) Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 43(2):121-126
72. Loeys B, De Paepe A (2008) New insights in the pathogenesis of aortic aneurysms. Verh K Acad Geneeskd Belg 70(2):69-84
73. Coucke PJ et al (2006) Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 38(4):452-457
74. Shprintzen RJ, Goldberg RB (1982) A recurrent pattern syndrome of craniosynostosis associated with arachnodactyly and abdominal hernias. J Craniofac Genet Dev Biol 2(1):65-74
75. Greally MT et al (1998) Shprintzen-Goldberg syndrome: A clinical analysis. Am J Med Genet 76(3):202-212
76. Akutsu K et al (2007) Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factorbeta receptor genes. Circ J 71(8):1305-1309
77. Greally MT (1993) Shprintzen-Goldberg syndrome. In: Pagon RA et al (eds) Gene reviews. University of Washington, Seattle
78. Robinson PN et al (2005) Shprintzen-Goldberg syndrome: Fourteen new patients and a clinical analysis. Am J Med Genet A 135(3):251-262
79. Ades LC et al (1995) Distinct skeletal abnormalities in four girls with Shprintzen-Goldberg syndrome. Am J Med Genet 57(4):565-572
80. Ades LC et al (2006) FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation Disorders revisited. Am J Med Genet A 140(10): 1047-1058
81. Ng CM (2004) TGF- -dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114(11):1586-1592
82. Girdauskas E et al (2011) Transforming growth factor- beta receptor type-II mutation in a patient with bicuspid aortic valve disease and intraoperative aortic dissection. Ann Thorac Surg 91(5):e70-e71
83. Rendu H (1896) Epistaxis repetees chez un sujet porteur de petits angiomes cutanes et muquez. Gazette des Hopitaux Civils et Militaires (Paris) 135:1322
84. Osler W (1901) On a family form of recurring epistaxis, associated with multiple telangectases of the skin and mucous membranes. Bull Johns Hopkins Hosp 12:333
85. Weber F (1907) Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring hemorrhages. Lancet 2:160-162
86. Kjeldsen AD, Vase P, Green A (1999) Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients. J Intern Med 245(1):31-39
87. Bideau A et al (1989) Epidemiological investigation of Rendu-Osler disease in France: Its geographical distribution and prevalence. Popul Engl Sel 44(1):3-22
88. Shovlin CL et al (2008) Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 63(3):259-266
89. Bourdeau A, Dumont DJ, Letarte M (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104(10):1343-1351
90. Wallace GM, Shovlin CL (2000) A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 55(8):685-690
91. Cole SG et al (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42(7):577-582
92. Plauchu H et al (1989) Age-related clinical profi le of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32(3):291-297
93. Pasculli G et al (2005) Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia. QJM 98(10):757-763
94. Fulbright RK et al (1998) MR of hereditary hemorrhagic telangiectasia: Prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 19(3):477-484
95. Cottin V et al (2004) Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 169(9):994-1000
96. Piantanida M et al (1996) Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 33(6):441-443
97. Govani FS, Shovlin CL (2009) Hereditary haemorrhagic telangiectasia: A clinical and scientifi c review. Eur J Hum Genet 17(7):860-871
98. Shovlin CL et al (2007) Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): Association with venous thromboembolism. Thromb Haemost 98(5):1031-1039
99. Cirulli A et al (2006) Patients with Hereditary Hemorrhagic Telangectasia (HHT) exhibit a defi cit of polymorphonuclear cell and monocyte oxidative burst and phagocytosis: A possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 12(10):1209-1215
100. Shovlin CL et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler- Weber syndrome). Am J Med Genet 91(1):66-67
101. Faughnan ME et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73-87
102. McAllister KA et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8(4):345-351
103. Berg JN et al (1997) The activin receptor-like kinase 1 gene: Genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 61(1):60-67
104. Johnson DW et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13(2):189-195
105. Andrabi S et al (2011) SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction. Am J Med Genet A 155A(5):1165-1169
106. Letarte M et al (2005) Reduced endothelial secretion and plasma levels of transforming growth factorbeta1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc Res 68(1):155-164
107. Roman BL et al (2002) Disruption of acvrl1 increases endothelial cell number in zebrafi sh cranial vessels. Development 129(12):3009-3019
108. Oh SP et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 97(6):2626-2631
109. Seki T, Yun J, Oh SP (2003) Arterial endotheliumspecifi c activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 93(7):682-689
110. Stefansson S et al (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276(11):8135-8141
111. Fernandez LA et al (2005) Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 68(2):235-248
112. Goumans MJ et al (2003) Activin receptorlike kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK-5 signaling. Mol Cell 12(4):817-828
113. Davies RJ et al (2012) BMP type-II receptor defi - ciency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: Role of proinfl ammatory cytokines. Am J Physiol Lung Cell Mol Physiol 302(6):L604-L615
114. West J et al (2004) Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94(8):1109-1114
115. Kimura N et al (2000) BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275(23):17647-17652
116. Trembath RC et al (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. New Engl J Med 345(5):325-334
117. You HJ et al (2007) The type-III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28(12):2491-2500
118. Hawinkels LJ, Ten Dijke P (2011) Exploring anti- TGF- beta therapies in cancer and fi brosis. Growth Factors 29(4):140-152
119. Rico MC et al (2008) Thrombospondin-1 and transforming growth factor beta are pro-infl ammatory molecules in rheumatoid arthritis. Transl Res 152(2):95-98
120. Rico MC et al (2010) The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: An emerging therapeutic target in rheumatoid arthritis. Curr Vasc Pharmacol 8(3):338-343
121. Wahl SM, Chen W (2005) Transforming growth factor-beta-induced regulatory T cells referee infl ammatory and autoimmune diseases. Arthritis Res Ther 7(2):62-68
122. Ohtsuka K et al (1998) Decreased production of TGFbeta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 160(5):2539-2545
123. Mageed RA, Prud'homme GJ (2003) Immunopathology and the gene therapy of lupus. Gene Ther 10(10):861-874
124. Hiratzka LF et al (2010) ACCF/AHA/AATS/ACR/ ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121(13):e266-e369
125. Coady MA, Rizzo JA, Elefteriades JA (1999) Developing surgical intervention criteria for thoracic aortic aneurysms. Cardiol Clin 17(4):827-839
126. Coady MA et al (1999) Surgical intervention criteria for thoracic aortic aneurysms: A study of growth rates and complications. Ann Thorac Surg 67(6):1922-1926, discussion 1953-1958
127. Elefteriades JA (2002) Natural history of thoracic aortic aneurysms: Indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 74(5):S1877-S1880, discussion S1892-S1898
128. Lobato AC, Puech-Leao P (1998) Predictive factors for rupture of thoracoabdominal aortic aneurysm. J Vasc Surg 27(3):446-453
129. Svensson LG et al (1989) Appraisal of adjuncts to prevent acute renal failure after surgery on the thoracic or thoracoabdominal aorta. J Vasc Surg 10(3):230-239
130. Svensson LG et al (1993) Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 17(2):357-368, discussion 368-370
131. Bobik A (2006) Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 26(8):1712-1720
132. Ikonomidis JS et al (2006) Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 114(1 Suppl):I365-I370
133. Kapoun AM et al (2006) Transforming growth factor- beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofi broblast differentiation and profi brotic gene expression. Mol Pharmacol 70(2):518-531
134. Hu Y et al (2006) Role of extracellular signalregulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fi broblasts in vitro. Lung 184(1):33-42
135. Greenberg RK et al (2008) Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: A comparison of endovascular and open techniques. Circulation 118(8):808-817
136. Makaroun MS et al (2008) Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. J Vasc Surg 47(5):912-918
137. Yetman AT, Bornemeier RA, McCrindle BW (2005) Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 95(9):1125-1127
138. Kubo A et al (2000) Angiotensin II regulates the cell cycle of vascular smooth muscle cells from SHR. Am J Hypertens 13(10):1117-1124
139. Habashi JP et al (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117-121
140. Habashi JP et al (2011) Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332(6027):361-365
141. Judge DP et al (2011) Mitral valve disease in Marfan syndrome and related disorders. J Cardiovasc Transl Res 4(6):741-747
142. Holm TM et al (2011) Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332(6027):358-361
143. Milewicz DM, Carlson AA, Regalado ES (2010) Genetic testing in aortic aneurysm disease: PRO. Cardiol Clin 28(2):191-197
144. Sood S et al (1996) Mutation in fi brillin-1 and the Marfanoid- craniosynostosis (Shprintzen-Goldberg) syndrome. Nat Genet 12(2):209-211
145. Kosaki K et al (2006) Molecular pathology of Shprintzen-Goldberg syndrome. Am J Med Genet A 140(1):104-108, author reply 109-110
146. van Steensel MA et al (2008) Shprintzen-Goldberg syndrome associated with a novel missense mutation in TGFBR2. Exp Dermatol 17(4):362-365
147. Stheneur C et al (2008) Identifi cation of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype- Investigations in 457 patients with Marfan syndrome type-I and II, Loeys-Dietz syndrome and related disorders. Hum Mutat 29(11):E284-E295
148. Kuhnel TS et al (2005) Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 19(5):508-513
149. Buscarini E et al (2006) Liver involvement in hereditary hemorrhagic telangiectasia: Consensus recommendations. Liver Int 26(9):1040-1046
150. Cohen JH et al (2005) Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. Am J Med Genet A 137(2):153-160
151. Abdalla SA, Letarte M (2006) Hereditary haemorrhagic telangiectasia: Current views on genetics and mechanisms of disease. J Med Genet 43(2):97-110
152. Rifkin DB, Todorovic V (2010) Bone matrix to growth factors: Location, location, location. J Cell Biol 190(6):949-951
153. Atsawasuwan P et al (2008) Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. J Biol Chem 283(49):34229-34240
154. Fernandez LA et al (2006) Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGFbeta signaling pathway. Clin Med Res 4(1):66-78
155. Gleason TG (2005) Heritable disorders predisposing to aortic dissection. Semin Thorac Cardiovasc Surg 17(3):274-281
156. Pannu H et al (2005) Mutations in transforming growth factor-beta receptor type-II cause familial thoracic aortic aneurysms and dissections. Circulation 112(4):513-520
157. Callewaert BL et al (2008) Arterial tortuosity syndrome: Clinical and molecular fi ndings in 12 newly identifi ed families. Hum Mutat 29(1):150-158
158. van De Laar IM et al (2012) Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 49(1):47-57